Theratechnologies, Inc. (THTX) News
Filter THTX News Items
THTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
THTX News Highlights
- THTX's 30 day story count now stands at 2.
- Over the past 8 days, the trend for THTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BASE and DEC are the most mentioned tickers in articles about THTX.
Latest THTX News From Around the Web
Below are the latest news stories about THERATECHNOLOGIES INC that investors may wish to consider to help them evaluate THTX as an investment opportunity.
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration StatementTheratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3. |
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading DoseUpdated label means new Trogarzo® patients no longer require initiation of treatment by 30-minute infusionComplete IV push method enables easier and more convenient administration of Trogarzo® for heavily treatment-experienced adults with HIV This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Theratechn |
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation AwardHonor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancerMONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSR |
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementThis news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement datedDecember 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers investors will want to watch this morning. |
CHPT Stock: ChargePoint Unveils New Software Solutions for Fleet ManagementChargePoint stock is on the move Thursday as investors in CHPT react to the release of a new suite of tools for fleet owners. |
PLTR Stock Alert: Study Ranks Palantir as Top AI VendorPalantir Technologies stock is in the news as PLTR investors react to the company being named the top AI vendor for 2023. |
Why Is Theratechnologies (THTX) Stock Down 22% Today?Theratechnologies stock is falling hard on Thursday after the company priced a public offering and private placement for THTX shares. |
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementThis news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Common shares priced at US$1.00 per share MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that i |
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private PlacementThis news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering (the “P |